Autologous stromal vascular fraction therapy for rheumatoid arthritis: Rationale and clinical safety

International Archives of Medicine

Volumn 5, Issue 1, 2012, Pages

  Rodriguez, Jorge Paz ^a   Murphy, Michael P ^b   Hong, Soonjun ^b   Madrigal, Marialaura ^a   March, Keith L ^b   Minev, Boris ^c   Harman, Robert J ^d   Chen, Chien Shing ^e   Timmons, Ruben Berrocal ^f   Marleau, Annette M ^g   Riordan, Neil H ^a  

^a Medistem Panama   (Panama)

^b INDIANA UNIVERSITY   (United States)

^c UNIVERSITY OF SAN DIEGO   (United States)

^d Vet Stem Inc   (United States)

^e LOMA LINDA UNIVERSITY   (United States)

^f Tecnología e innovación   (Panama)

^g INSTITUTE FOR MOLECULAR MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; FIBROBLAST GROWTH FACTOR; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN;

ADIPOSE TISSUE CELL; ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; AUTOLOGOUS STROMAL VASCULAR FRACTION THERAPY; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; ENDOTHELIAL PROGENITOR CELL; FEVER; FLUSHING; GRAFT FAILURE; HEART FAILURE; HEART MUSCLE; HUMAN; HYPOXIA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESOBLASTIC NEPHROMA; MYALGIA; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; RHEUMATOID ARTHRITIS; T LYMPHOCYTE ACTIVATION; TELOMERE; TREATMENT OUTCOME;

EID: 84863295482     PISSN: None     EISSN: 17557682     Source Type: Journal    
DOI: 10.1186/1755-7682-5-522313603     Document Type: Review

References (153)

1. Kim ES, et al: Intratracheal transplantation of human umbilical cord blood-derived mesenchymal stem cells attenuates escherichia coli-induced acute lung injury in mice. Respir Res 2011, 12(1):108.
2. Roddy GW, et al: Action at a distance: systemically administered adult stem/progenitor cells (MSCs) reduce inflammatory damage to the cornea without engraftment and primarily by secretion of TSG-6. Stem Cells 2011, 29:1572-9.
3. Sun CK, et al: Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med 2011, 9:118.
4. Weil BR, et al: Intravenous infusion of mesenchymal stem cells is associated with improved myocardial function during endotoxemia. Shock 2011, 36(3):235-241.
5. Macdonald GI, Augello A, De Bari C: Mesenchymal stem cells: reestablishing immunological tolerance in autoimmune rheumatic diseases. Arthritis and Rheumatism 2011, 63(9):2547-2557.
6. Choi H, et al: Anti-inflammatory protein TSG-6 secreted by activated MSCs attenuates zymosan-induced mouse peritonitis by decreasing TLR2/NF-{kappa}B signaling in resident macrophages. Blood 2011, 118(2):330-338.
7. Ringden O, Le Blanc K: Mesenchymal stem cells for treatment of acute and chronic graft-versus-host disease, tissue toxicity and hemorrhages Best practice & research. Clin Haem 2011, 24(1):65-72.
8. Dazzi F, Krampera M: Mesenchymal stem cells and autoimmune diseases. Best practice & research. Clin Haem 2011, 24(1):49-57.
9. Vassalli G, Moccetti T: Cardiac repair with allogeneic mesenchymal stem cells after myocardial infarction. Swiss Med Weekly 2011, 141:13209.
10. Poncelet AJ, et al: Intracardiac allogeneic mesenchymal stem cell transplantation elicits neo-angiogenesis in a fully immunocompetent ischaemic swine model. European journal of cardio-thoracic surgery: official journal of the European Association for Cardio-thoracoc Surgery 2010, 38(6):781-787.
11. Chen L, et al: Analysis of allogenicity of mesenchymal stem cells in engraftment and wound healing in mice. PLoS One 2009, 4(9):e7119.
12. Weiss ML, et al: Immune properties of human umbilical cord Wharton's jelly-derived cells. Stem Cells 2008, 26(11):2865-2874.
13. Lin YT, et al: Human mesenchymal stem cells prolong survival and ameliorate motor deficit through trophic support in huntington's disease mouse models. PLoS One 2011, 6(8):e22924.
14. Shabbir A, et al: Activation of host tissue trophic factors through JAKSTAT3 signaling: a mechanism of mesenchymal stem cell-mediated cardiac repair. Am J Physiol Heart Circ Physiol 2010, 299(5):H1428-1438.
15. Khoo ML, et al: Transplantation of neuronal-primed human bone marrow mesenchymal stem cells in hemiparkinsonian rodents. PLoS One 2011, 6(5):e19025.
16. Hu S, et al: Isolated coronary artery bypass graft combined with bone marrow mononuclear cells delivered through a graft vessel for patients with previous myocardial infarction and chronic heart failure: a single-center, randomized, double-blind, placebo-controlled clinical trial. J Am Coll Cardiol 2011, 57(24):2409-2415.
17. Williams AR, et al: Intramyocardial stem cell injection in patients with ischemic cardiomyopathy: functional recovery and reverse remodeling. Circ Res 2011, 108(7):792-796.
18. Adler DS, et al: Safety and efficacy of bone marrow-derived autologous CD133+ stem cell therapy. Front Biosci 2011, 3:506-514.
19. Subrammaniyan R, et al: Application of autologous bone marrow mononuclear cells in six patients with advanced chronic critical limb ischemia as a result of diabetes: our experience. Cytotherapy 2011, 13(8):993-999.
20. Gabr H, et al: Limb salvage using intramuscular injection of unfractionated autologous bone marrow mononuclear cells in critical limb ischemia: a prospective pilot clinical trial. Experimental and clinical transplantation: official journal of the Middle East Society for Organ Transplantation 2011, 9(3):197-202.
21. Murphy MP, et al: Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. Journal of vascular surgery: official publication, the Society for Vascular Surgery [and] International Society for Cardiovascular Surgery, North American Chapter 2011, 53(6):1565-1574e1.
22. Jiang R, et al: Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Front Med 2011, 5(1):94-100.
23. Davatchi F, et al: Mesenchymal stem cell therapy for knee osteoarthritis. Preliminary report of four patients. Int J Rheum Dis 2011, 14(2):211-215.
24. Honmou O, et al: Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain:J Neurol 2011, 134(Pt 6):1790-1807.
25. Karussis D, et al: Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 2010, 67(10):1187-1194.
26. Chen Y, Wang G, Zeng L: Adipose tissue or bone marrow, store for purchasing mesenchymal stem cells? Circulation journal: official journal of the Japanese Circulation Society 2011, 75(9):2260-8.
27. Mirsaidi A, et al: Telomere length, telomerase activity and osteogenic differentiation are maintained in adipose-derived stromal cells from senile osteoporotic SAMP6 mice. Journal of tissue engineering and regenerative medicine 2011.
28. Chen HT, et al: Proliferation and differentiation potential of human adipose-derived mesenchymal stem cells isolated from elderly patients with osteoporotic fractures. Journal of cellular and molecular medicine 2011.
29. Ichim TE, et al: Autologous stromal vascular fraction cells: a tool for facilitating tolerance in rheumatic disease. Cell Immunol 2010, 264(1):7-17.
30. Hollenberg CH, Vost A: Regulation of DNA synthesis in fat cells and stromal elements from rat adipose tissue. J Clin Invest 1969, 47(11):2485-2498.
31. Gaben-Cogneville AM, et al: Differentiation under the control of insulin of rat preadipocytes in primary culture. Isolation of homogeneous cellular fractions by gradient centrifugation. Biochim Biophys Acta 1983, 762(3):437-444.
32. Zuk PA, et al: Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng 2001, 7(2):211-228. (Pubitemid 32295155)
33. Zuk PA, et al: Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002, 13(12):4279-4295. (Pubitemid 35471185)
34. Faustini M, et al: Nonexpanded mesenchymal stem cells for regenerative medicine: yield in stromal vascular fraction from adipose tissues. Tissue Eng Part C, Methods 2010, 16(6):1515-1521.
35. Garcia-Olmo D, et al: A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 2005, 48(7):1416-1423. (Pubitemid 40933870)
36. Stillaert FB, et al: Human clinical experience with adipose precursor cells seeded on hyaluronic acid-based spongy scaffolds. Biomaterials 2008, 29(29):3953-3959.
37. Garcia-Olmo D, Garcia-Arranz M, Herreros D: Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Expert Opin Biol Ther 2008, 8(9):1417-1423.
38. Fang B, et al: Treatment of severe therapy-resistant acute graft-versushost disease with human adipose tissue-derived mesenchymal stem cells. Bone Marrow Transplant 2006, 38(5):389-390.
39. Fang B, et al: Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc 2007, 39(5):1710-1713. (Pubitemid 46907940)
40. Fang B, et al: Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007, 39(10):3358-3362. (Pubitemid 350251475)
41. Hayashi O, et al: Comparison of osteogenic ability of rat mesenchymal stem cells from bone marrow, periosteum, and adipose tissue. Calcif Tissue Int 2008, 82(3):238-247.
42. Noel D, et al: Cell specific differences between human adipose-derived and mesenchymal-stromal cells despite similar differentiation potentials. Exp Cell Res 2008, 314(7):1575-1584.
43. Kim Y, et al: Direct comparison of human mesenchymal stem cells derived from adipose tissues and bone marrow in mediating neovascularization in response to vascular ischemia. Cell Physiol Biochem 2007, 20(6):867-876. (Pubitemid 350059730)
44. Ikegame Y, et al: Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy 2011, 13(6):675-685.
45. Keyser KA, Beagles KE, Kiem HP: Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. Cell Transplant 2007, 16(5):555-562. (Pubitemid 351448291)
46. Vet-Stem Cell Therapy: Arthritis in Dogs and Cats/Tendons, Ligaments &Joints in Horses. [http://www.vet-stem.com], Last accessed on 01-30-2012.
47. Black LL, et al: Effect of adipose-derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther 2007, 8(4):272-284. (Pubitemid 351419393)
48. Black LL, et al: Effect of intraarticular injection of autologous adiposederived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther 2008, 9(3):192-200.
49. Lin K, et al: Characterization of adipose tissue-derived cells isolated with the Celution system. Cytotherapy 2008, 10(4):417-426. (Pubitemid 351983165)
50. Tissue Genesis, Inc. [http://www.tissuegenesis.com], Last accessed on 01-30-2012.
51. Hang-Fu L, Marmolya G, Feiglin DH: Liposuction fat-fillant implant for breast augmentation and reconstruction. Aesthetic Plast Surg 1995, 19(5):427-437.
52. Klein AW: Skin filling. Collagen and other injectables of the skin. Dermatol Clin 2001, 19(3):491-508.
53. Riordan NH, et al: Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Translational Med 2009, 7:29.
54. Knowlton D: Fifth Annual Stem Cell Summit. IDrugs: Invest Drugs J 2010, 13(4):235-238.
55. Hare JM, et al: A randomized, double-blind, placebo-controlled, doseescalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009, 54(24):2277-2286.
56. Wernicke CM, et al: Mesenchymal stromal cells for treatment of steroidrefractory GvHD: a review of the literature and two pediatric cases. Int Arch Med 2011, 4(1):27.
57. Baek SJ, Kang SK, Ra JC: In vitro migration capacity of human adiposederived mesenchymal stem cells and their expression of a distinct set of chemokine and growth factor receptors. Experimental & molecular medicine 2011, 43(10):596-603.
58. Shi M, et al: Regulation of CXCR4 expression in human mesenchymal stem cells by cytokine treatment: role in homing efficiency in NOD/SCID mice. Haematol 2007, 92(7):897-904. (Pubitemid 350144236)
59. Puglisi MA, et al: Adipose tissue-derived mesenchymal stem cells and hepatic differentiation: old concepts and future perspectives. European Rev Med Pharmacol Sci 2011, 15(4):355-364.
60. Ding DC, Shyu WC, Lin SZ: Mesenchymal stem cells. Cell Transplant 2011, 20(1):5-14.
61. Caplan AI, Dennis JE: Mesenchymal stem cells as trophic mediators. J Cell Biochem 2006, 98(5):1076-1084. (Pubitemid 44128350)
62. Meirelles Lda S, et al: Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev 2009, 20(5-6):419-427.
63. Uccelli A, et al: Neuroprotective features of mesenchymal stem cells. Best practice & research. Clin Haem 2011, 24(1):59-64.
64. Lu Y, et al: Mesenchymal stem cells protect islets from hypoxia/ reoxygenation-induced injury. Cell Biochem Funct 2010, 28(8):637-643.
65. Murohara T, Shintani S, Kondo K: Autologous adipose-derived regenerative cells for therapeutic angiogenesis. Curr Pharm Des 2009, 15(24):2784-2790.
66. Ichim TE, et al: Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol 2010, 260(2):75-82.
67. Chen PM, et al: Immunomodulatory properties of human adult and fetal multipotent mesenchymal stem cells. J Biomed Sci 2011, 18:49.
68. Pittenger MF, et al: Multilineage potential of adult human mesenchymal stem cells. Sci 1999, 284(5411):143-147. (Pubitemid 29282067)
69. Aust L, et al: Yield of human adipose-derived adult stem cells from liposuction aspirates. Cytotherapy 2004, 6(1):7-14. (Pubitemid 38325114)
70. Premaratne GU, et al: Stromal vascular fraction transplantation as an alternative therapy for ischemic heart failure: anti-inflammatory role. J 7Cardiothorac Surg 2011, 6:43.
71. de la Garza-Rodea AS, et al: Myogenic properties of human mesenchymal stem cells derived from three different sources. Cell transplantation 2011.
72. Vidal MA, et al: Evaluation of senescence in mesenchymal stem cells isolated from equine bone marrow, adipose tissue, and umbilical cord tissue. Stem cells and development 2012, 21(2):273-283.
73. Mendelson A, et al: Chondrogenesis by chemotactic homing of synovium, bone marrow, and adipose stem cells in vitro. The FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2011, 25(10):3496-504.
74. Tse KH, et al: Adipose tissue and bone marrow-derived stem cells react similarly in an ischaemia-like microenvironment. Journal of tissue engineering and regenerative medicine 2011.
75. Niemeyer P, et al: Comparison of immunological properties of bone marrow stromal cells and adipose tissue-derived stem cells before and after osteogenic differentiation in vitro. Tissue Eng 2007, 13(1):111-121. (Pubitemid 46175533)
76. Zhang X, et al: Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissue. J Cell Biochem 2011, 112(4):1206-1218.
77. Najar M, et al: Mesenchymal stromal cells use PGE2 to modulate activation and proliferation of lymphocyte subsets: Combined comparison of adipose tissue, Wharton's Jelly and bone marrow sources. Cell Immunol 2010, 264(2):171-179.
78. Najar M, et al: Adipose-tissue-derived and Wharton's jelly-derived mesenchymal stromal cells suppress lymphocyte responses by secreting leukemia inhibitory factor. Tissue Eng Part A 2010, 16(11):3537-3546.
79. Wagner W, Ho AD: Mesenchymal stem cell preparations-comparing apples and oranges. Stem Cell Rev 2007, 3(4):239-248. (Pubitemid 351526200)
80. Ra JC, et al: Safety of intravenous infusion of human adipose tissue-derived mesenchymal stem cells in animals and humans. Stem Cells Dev 2011, 20(8):1297-1308.
81. Vanikar AV, et al: Cotransplantation of adipose tissue-derived insulin-secreting mesenchymal stem cells and hematopoietic stem cells: a novel therapy for insulin-dependent diabetes mellitus. Stem Cells Int 2010, 2010:582382.
82. Garcia-Olmo D, et al: Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009, 52(1):79-86.
83. Caimi PF, et al: Emerging therapeutic approaches for multipotent mesenchymal stromal cells. Curr Opin Hematol 2010, 17(6):505-513.
84. Singer NG, Caplan AI: Mesenchymal stem cells: mechanisms of inflammation. Annual Rev Pathol 2011, 6:457-478.
85. Lindroos B, Suuronen R, Miettinen S: The potential of adipose stem cells in regenerative medicine. Stem Cell Rev 2011, 7(2):269-291.
86. Cho KS, Roh HJ: Immunomodulatory effects of adipose-derived stem cells in airway allergic diseases. Current Stem Cell Res Therapy 2010, 5(2):111-115.
87. Ringden O, et al: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplant 2006, 81(10):1390-1397. (Pubitemid 43847148)
88. Le Blanc K, et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008, 371(9624):1579-1586. (Pubitemid 351626841)
89. Fang B, et al: Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease. Transplant Proc 2007, 39(10):3358-3362. (Pubitemid 350251475)
90. Fang B, et al: Using human adipose tissue-derived mesenchymal stem cells as salvage therapy for hepatic graft-versus-host disease resembling acute hepatitis. Transplant Proc 2007, 39(5):1710-1713. (Pubitemid 46907940)
91. Chang X, Zheng P, Liu Y: FoxP3: a genetic link between immunodeficiency and autoimmune diseases. Autoimmun Rev 2006, 5(6):399-402. (Pubitemid 44143032)
92. Bacchetta R, et al: Defective regulatory and effector T cell functions in patients with FOXP3 mutations. J Clin Investig 2006, 116(6):1713-1722.
93. Schubert LA, et al: Scurfin (FOXP3) acts as a repressor of transcription and regulates T cell activation. J Biol Chem 2001, 276(40):37672-37679.
94. Rudensky AY, Regulatory T: Cells and Foxp3. Immunol Rev 2011, 241(1):260-268.
95. Correale J, Villa A: Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis. Ann Neurol 2010, 67(5):625-638.
96. Fransson M, et al: T regulatory cells lacking CD25 are increased in MS during relapse. Autoimmunity 2010, 43(8):590-597.
97. Frisullo G, et al: CD8(+)Foxp3(+) T cells in peripheral blood of relapsing-remitting multiple sclerosis patients. Hum Immunol 2010, 71(5):437-441.
98. Braitch M, et al: Glucocorticoids increase CD4CD25 cell percentage and Foxp3 expression in patients with multiple sclerosis. Acta Neurol Scand 2009, 119(4):239-245.
99. Haas J, et al: Reduced suppressive effect of CD4 + CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005, 35(11):3343-3352. (Pubitemid 41672538)
100. Kavousanaki M, et al: Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy. Arthritis Rheum 2010, 62(1):53-63.
101. Sempere-Ortells JM, et al: Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28. Autoimmunity 2009, 42(8):636-645.
102. Esensten JH, Wofsy D, Bluestone JA: Regulatory T cells as therapeutic targets in rheumatoid arthritis. Nat Rev Rheumatol 2009, 5(10):560-565.
103. Flores-Borja F, et al: Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. Proc Natl Acad Sci USA 2008, 105(49):19396-19401.
104. Kao JK, Hsue YT, Lin Cy: Role of new population of peripheral CD11c(+) CD8(+) T cells and CD4(+)CD25(+) regulatory T cells during acute and remission stages in rheumatoid arthritis patients. Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi 2007, 40(5):419-427.
105. Zhang Y, et al: White adipose tissue cells are recruited by experimental tumors and promote cancer progression in mouse models. Cancer Res 2009, 69(12):5259-5266.
106. Yan B, et al: Dysfunctional CD4+, CD25+ regulatory T cells in untreated active systemic lupus erythematosus secondary to interferon-alpha-producing antigen-presenting cells. Arthritis Rheum 2008, 58(3):801-812. (Pubitemid 351364878)
107. Sfikakis PP, et al: Increased expression of the FoxP3 functional marker of regulatory T cells following B cell depletion with rituximab in patients with lupus nephritis. Clin Immunol 2007, 123(1):66-73. (Pubitemid 46401511)
108. Cipolletta D, et al: Tissular T(regs): a unique population of adipose-tissue-resident Foxp3 + CD4+ T cells that impacts organismal metabolism. Seminars in immunology 2011, 23(6):431-7.
109. Feuerer M, et al: Genomic definition of multiple ex vivo regulatory T cell subphenotypes. Proc Natl Acad Sci USA 2010, 107(13):5919-5924.
110. Feuerer M, et al: Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nature Med 2009, 15(8):930-939.
111. De Rosa V, et al: A key role of leptin in the control of regulatory T cell proliferation. Immunity 2007, 26(2):241-255. (Pubitemid 46329441)
112. Valencia X, et al: TNF downmodulates the function of human CD4 + CD25hi T-regulatory cells. Blood 2006, 108(1):253-261. (Pubitemid 43990636)
113. Chatenoud L: CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003, 3(2):123-132.
114. Asahara T, et al: Isolation of putative progenitor endothelial cells for angiogenesis. Sci 1997, 275(5302):964-967. (Pubitemid 27087709)
115. Kupatt C, et al: Retroinfusion of embryonic endothelial progenitor cells attenuates ischemia-reperfusion injury in pigs: role of phosphatidylinositol 3-kinase/AKT kinase. Circulation 2005, 112(9 Suppl): I117-122. (Pubitemid 41266662)
116. Aicher A, et al: Assessment of the tissue distribution of transplanted human endothelial progenitor cells by radioactive labeling. Circulation 2003, 107(16):2134-2139. (Pubitemid 36532196)
117. Fan Y, et al: Endothelial progenitor cell transplantation improves longterm stroke outcome in mice. Ann Neurol 2010, 67(4):488-497.
118. Lam CF, et al: Transplantation of endothelial progenitor cells improves pulmonary endothelial function and gas exchange in rabbits with endotoxin-induced acute lung injury. Anesth Analg 2011, 112(3):620-627.
119. Mao M, et al: Intravenous delivery of bone marrow-derived endothelial progenitor cells improves survival and attenuates lipopolysaccharide-induced lung injury in rats. Shock 2010, 34(2):196-204.
120. Kahler CM, et al: Peripheral infusion of rat bone marrow derived endothelial progenitor cells leads to homing in acute lung injury. Respir Res 2007, 8:50.
121. Elkhafif N, et al: CD133(+) human umbilical cord blood stem cells enhance angiogenesis in experimental chronic hepatic fibrosis. APMIS: Acta Path, Micro, Im Scand 2011, 119(1):66-75.
122. Liu F, et al: Transplanted endothelial progenitor cells ameliorate carbon tetrachloride-induced liver cirrhosis in rats. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 2009, 15(9):1092-1100.
123. Nakamura T, et al: Significance and therapeutic potential of endothelial progenitor cell transplantation in a cirrhotic liver rat model. Gastroenterology 2007, 133(1):91-107 e1.
124. Wang SH, et al: Late outgrowth endothelial cells derived from Wharton jelly in human umbilical cord reduce neointimal formation after vascular injury: involvement of pigment epithelium-derived factor. Arterioscler Thromb Vasc Biol 2009, 29(6):816-822.
125. Desouza CV, et al: Role of inflammation and insulin resistance in endothelial progenitor cell dysfunction. Diabetes 2011, 60(4):1286-1294.
126. Orlic D, et al: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci USA 2001, 98(18):10344-10349. (Pubitemid 32803022)
127. Zhang L, et al: Granulocyte colony-stimulating factor treatment ameliorates liver injury and improves survival in rats with dgalactosamine- induced acute liver failure. Toxicology letters 2011, 204(1):92-9.
128. Cho HJ, et al: Mobilized endothelial progenitor cells by granulocytemacrophage colony-stimulating factor accelerate reendothelialization and reduce vascular inflammation after intravascular radiation. Circulation 2003, 108(23):2918-2925.
129. Lara-Hernandez R, et al: Safety and efficacy of therapeutic angiogenesis as a novel treatment in patients with critical limb ischemia. Ann Vasc Surg 2010, 24(2):287-294.
130. Kim DI, et al: Angiogenesis facilitated by autologous whole bone marrow stem cell transplantation for Buerger's disease. Stem Cells 2006, 24(5):1194-1200.
131. Mund JA, et al: Endothelial progenitor cells and cardiovascular cell-based therapies. Cytotherapy 2009, 11(2):103-113.
132. Katritsis DG, et al: Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace: European pacing, arrhythmias, and cardiac electrophysiology: journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology 2007, 9(3):167-171.
133. Auxenfans C, et al: Adipose-derived stem cells (ASCs) as a source of endothelial cells in the reconstruction of endothelialized skin equivalents. Journal of tissue engineering and regenerative medicine 2011.
134. Martinez-Estrada OM, et al: Human adipose tissue as a source of Flk-1+ cells: new method of differentiation and expansion. Cardiovasc Res 2005, 65(2):328-333. (Pubitemid 40082474)
135. Miranville A, et al: Improvement of postnatal neovascularization by human adipose tissue-derived stem cells. Circulation 2004, 110(3):349-355. (Pubitemid 38955505)
136. Sumi M, et al: Transplantation of adipose stromal cells, but not mature adipocytes, augments ischemia-induced angiogenesis. Life Sci 2007, 80(6):559-565. (Pubitemid 46038328)
137. Planat-Benard V, et al: Plasticity of human adipose lineage cells toward endothelial cells: physiological and therapeutic perspectives. Circulation 2004, 109(5):656-663. (Pubitemid 38198874)
138. Nakagami H, et al: Novel autologous cell therapy in ischemic limb disease through growth factor secretion by cultured adipose tissue-derived stromal cells. Arterioscler Thromb Vasc Biol 2005, 25(12):2542-2547. (Pubitemid 43732276)
139. Rehman J, et al: Secretion of angiogenic and antiapoptotic factors by human adipose stromal cells. Circulation 2004, 109(10):1292-1298. (Pubitemid 38372789)
140. Cai L, et al: Suppression of hepatocyte growth factor production impairs the ability of adipose-derived stem cells to promote ischemic tissue revascularization. Stem Cells 2007, 25(12):3234-3243. (Pubitemid 350294449)
141. Bouffi C, et al: IL-6-dependent PGE2 secretion by mesenchymal stem cells inhibits local inflammation in experimental arthritis. PLoS One 2010, 5(12):e14247.
142. Mao F, et al: Immunosuppressive effects of mesenchymal stem cells in collagen-induced mouse arthritis. Inflammation research: official journal of the European Histamine Research Society 2010, 59(3):219-225.
143. Gonzalez MA, et al: Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheum 2009, 60(4):1006-1019.
144. Liu Y, et al: Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Therapy 2010, 12(6):R210.
145. Augello A, et al: Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum 2007, 56(4):1175-1186. (Pubitemid 46608642)
146. Miyamoto C, et al: Osteogenic protein-1 with transforming growth factorbeta1: potent inducer of chondrogenesis of synovial mesenchymal stem cells in vitro. Journal of orthopaedic science: official journal of the Japanese Orthopaedic Association 2007, 12(6):555-561.
147. de Kleer IM, et al: CD4 + CD25bright regulatory T cells actively regulate inflammation in the joints of patients with the remitting form of juvenile idiopathic arthritis. J Immunol 2004, 172(10):6435-6443.
148. Popov I, et al: Preventing autoimmune arthritis using antigen-specific immature dendritic cells: a novel tolerogenic vaccine. Arthritis Res Therapy 2006, 8(5):R141.
149. Ichim TE, et al: Antigen-specific therapy of rheumatoid arthritis. Expert Opin Biol Ther 2008, 8(2):191-199. (Pubitemid 351233712)
150. Zheng X, et al: RNAi-mediated CD40-CD154 interruption promotes tolerance in autoimmune arthritis. Arthritis Res Therapy 2010, 12(1):R13.
151. Zheng X, et al: Treatment of autoimmune arthritis using RNA interference-modulated dendritic cells. J Immunol 2010, 184(11):6457-6464.
152. Zhou Y, et al: The therapeutic efficacy of human adipose tissue-derived mesenchymal stem cells on experimental autoimmune hearing loss in mice. Immunology 2011, 133(1):133-140.
153. Madonna R, De Caterina R: Adipose tissue: a new source for cardiovascular repair. Journal Cardiovasc Meds 2010, 11(2):71-80.